Lazertinib 160mg in EGFR T790M NSCLC

Summary

The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI. The current recommended dosage is 240mg. Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.

Timeline

Start

2023-02-01

Primary completion

2024-01-31

Completion

2025-01-31

Drugs

Indications